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Breast cancer has the highest incidence of all neoplastic diseases affecting US women 
(CDC, 2015). Moreover, breast cancer frequency among White women (122/100,000) 
exceeds that among Black women (117/100,000 -- CDC, 2015). Nonetheless, mortality from 
breast cancer is higher among Black women. This is especially true for older non-Hispanics. 
In 2014, the most recent year for which data is available (Centers for Disease Control and 
Prevention, 2016), the US breast cancer mortality rate (and 95% Confidence Intervals) 
among Black women ages 65 to 84 years was 102.65 (98.24, 107.05) for non-Hispanics and 
37.75 (24.88, 54.92) for Hispanics while corresponding values for White women were 84.84 
(83.43, 86.25) and 58.14 (54.38, 61.91). In contrast, the mortality rate for Black women ages 
35 to 64 years was 36.28 (35.01, 37.55) for non-Hispanics and 9.19 (6.60, 12.47) for 
Hispanics, while corresponding values for White women were 21.33 (20.90, 21.75) and 
17.59 (16.68, 18.49). Moreover, the US Black-White mortality gap has been widening for 
several decades (Hunt et al., 2014). Explanations for this phenomenon have identified later 
stages of cancer at the time of diagnosis (Chatterjee, He, & Keating, 2013; Silber et al., 
2013) and poor access to high quality care among Black women (Curtis, Quale, Haggstrom, 
& Smith-Bindman, 2008; Field et al., 2011; Hunt et al., 2014) as key problems. Specifically, 
significantly longer time intervals have been observed between abnormal mammogram and 
treatment initiation for Black women as compared to White women (Ashing-Giwa et al., 
2010; Bleicher et al., 2012; George et al., 2015; Gorin et al. 2006). In particularly, Gorin et 
al., (2006) reported that Black women ages 65 years and older were 1.39 times more likely 
to wait more than 60 days between an abnormal mammogram and a diagnostic biopsy, and 
1.64 times more likely to wait more than 30 days for treatment once breast cancer was 
diagnosed. Longer intervals between diagnostic biopsy and treatment among Black women 
relative to White women have also been apparent after controlling for insurance coverage, 
cancer stage, and age (Fedewa et al., 2011; Johnston, 2014).
The present study tested the hypotheses that the length of critical intervals between 
abnormal mammogram and breast cancer treatment within a large cohort of Medicare 
beneficiaries vary by age, race, and medical comorbidities.
Methods
Medicare Sample Selection
Administrative data from a cohort of randomly selected Medicare beneficiaries was 
purchased from the Center for Medicare and Medicaid Services (CMS). The cohort 
consisted of non-Hispanic Black and White beneficiaries ages 65 and older who resided in 
the continental United States and whose claims were tracked from 2005 to 2008. 
Beneficiaries who did not have out-patient service coverage (Medicare Part B) were 
excluded since screening mammography is generally an out-patient procedure. Also, 
beneficiaries receiving services from a Health Maintenance Organization (HMO) at any time 
during the observation period were excluded since HMO’s do not provide billing claims data 
to Medicare.
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Using Federal Information Processing Standard (FIPS) codes, we formulated a separate 
sampling frame for each continental US county or county-equivalent (the District of 
Columbia; parishes in Louisiana; and cities in Maryland, Missouri, and Virginia are all 
considered to be county equivalents), and stratified by race (Black or White). Unless there 
were fewer than 250 Black or 250 White beneficiaries, we randomly selected 250 Black 
women and 250 White women from each county. When there were fewer than 250, all 
beneficiaries from the group(s) with less than 250 beneficiaries were included. Race-age-
specific sampling weights were obtained by dividing the number of women in the Medicare 
Denominator File for each particular county by the race-age-specific number of women in 
that county. Since only 250 cases are needed in each group to provide sufficient power for 
racial comparisons (Cohen, 1992), the present data provide sufficient power to detect 
differences according to race.
Medicare Claims Selection and Definition of Screening and Diagnostic Mammograms
Outpatient, inpatient and physician (carrier) claims data for 2005–2008 were identified from 
the outpatient and carrier files, and then outpatient, inpatient, and physician files were linked 
to the claims for mammography using the following HCPCS (Healthcare Common 
Procedure Coding System) codes: 76082, 76090, 76091, 77051, 77055, 77056, G0203, 
G0204, G0205, and G0206 for diagnostic mammograms, and 76083, 76092, 77052, 77057, 
and G0202 for screening mammograms. Because coding errors preclude direct use of these 
HCPCS codes for defining screening mammograms as differentiated from diagnostic 
mammograms, we used algorithms specifically validated for that purpose to do so (Smith-
Bindman et al., 2006, Fenton et al, 2014). As part of this process, we also noted whether 
there was a diagnosis of a lump or breast mass (with the diagnosis codes of 611.72 or 217) at 
the time of mammography. Breast cancer diagnoses included the International Classification 
of Disease (ICD) 10 codes C50 and D05. Comorbidity was estimated with the Charlson 
score (Charlson et al., 1987).
Timeliness of Care
Times to biopsy following abnormal mammogram and to treatment following positive 
biopsy have been considered as quality of care indicators (Kaufman et al., 2010; 
Landercasper et al., 2010; Logan et al., 2013; Richardson et al., 2010). Among more than 
175 members of the National Consortium of Breast Centers (NCBC), the National Quality 
Measures for Breast Centers (NQMBC) program identified medians of 7 days for the 
former, 14 days for the latter and 28 days from abnormal mammogram to treatment 
(Kaufman et al., 2010) as measures of timely care. These were used for Cox proportional 
hazards modeling as described in the Analyses section (immediately below).
Analyses
All analyses accounted for weighting by utilizing survey procedures in SAS v9.23. The 
independent effects of age, race/ethnicity, and comorbidity were assessed with two types of 
multivariate analysis. Cox proportional hazard models were used to estimate outcomes 
specified as duration or waiting times, that is, the duration between events. Logistic 
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regression models were used to estimate the likelihood of a discrete event. Referent 
categories were assigned to assure that longer durations were associated with hazard/odds 
ratios greater than 1.0. In the logistic regression analyses, odds ratios indicated greater 
(>1.0) or lesser (<1.0) likelihood of receiving biopsies or treatment consistent with the 
aforementioned NQBMC median standards (Kaufman et al., 2010).
Approval
This study was approved by the Institutional Review Board of Tennessee State University.
Results
There were 4,476 women (weighted n=70,731) with a diagnosis of breast cancer included in 
these analyses (Figure 1). Table 1 shows that among women aged 65 to 84 years, the mean 
duration from abnormal mammogram to biopsy was 33.50 days (95% Confidence Interval 
(CI) 25.35, 41.65), with a median duration of 14 days. Additionally, the mean number of 
days from biopsy to treatment was 31.20 days (95% CI 29.04, 33.36) with a median of 23 
days. On average, the overall time from mammogram to treatment was 65.07 days (56.17, 
73.98), with a median of 40 days. As shown by consistently overlapping 95% CI’s, there 
were no statistically significant differences within each category (Mammogram to Biopsy, 
Biopsy to Treatment, and Mammogram to Treatment) according to age (65 to 74 or 75 to 
84), race (Black or White), or Charlson Comorbidity Coefficient (None, 1 or ≥ 2).
Table 2 shows results for Cox Proportional Hazard modeling for intervals longer than the 
aforementioned NQMBC medians. Black women had a significantly greater risk for longer 
duration between diagnostic biopsy and initiation of treatment (HR = 1.424, p=0.003), and 
between abnormal mammogram and initiation of treatment (HR=1.267, p=0.015). Table 3 
presents the likelihood of receiving biopsies or treatment consistent with the same NQMBC 
standards. Logistic regression indicated that none of the factors examined were significant 
predictors of longer duration in these data.
Discussion
In this cohort of non-Hispanic, Black or White Medicare beneficiaries residing in the 
continental US and receiving breast cancer treatment completely outside HMO settings 
between 2005 and 2008, the data support the hypothesis that Black race is associated with a 
delay between diagnostic biopsy and breast cancer treatment. Medical care delays may 
therefore be part of the reason for the widening racial gap in breast cancer mortality noted 
by Hunt et al. (2014). Many barriers related to health care utilization are more likely to 
affect Black women, including lack of transportation, fears of mammography-related pain, 
embarrassment, partner abandonment, inability to meet care giving and other obligations if a 
diagnosis of cancer were made, a belief that surgery may increase the chance of metastasis, 
lack of knowledge (about mammography, breast cancer risk factors, breast cancer treatment 
and breast cancer screening guidelines), poor health literacy, a propensity for placing a lower 
priority on prevention as compared with more acute problems, religious beliefs that “God 
will provide”, fatalism, and mistrust of the health care system (Bartle-Haring, 2010; 
Corrarino, 2015; Gerend & Pai, 2008). Additionally, Sheppard et al. (2013) observed a 
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significant difference in days between breast cancer surgery and chemotherapy initiation for 
Black women (72 days) in comparison to Whites (55 days). However, the difference was not 
significant after adjusting for self-reported quality of trust in the relationship with the 
treating physicians. Overall, the present data give evidence that the benefit of physician re-
imbursement provided to all members of the present cohort by Medicare may have been 
insufficient to overcome these additional barriers.
In addition to racial differences, the data suggest overall delays beyond the NQNBC 
benchmark equally affect Black women and White women. The median interval from 
abnormal mammogram to biopsy (14 days) was double the NQMBC median of 7 days, and 
the median of 23 days from biopsy to treatment initiation in these data was more than 60% 
greater than the NQMBC median of 14 days. Furthermore, the median of 40 days from 
abnormal mammogram to treatment initiation in these data was greater than the 29 days 
reported by Bleicher et al. (2012), who counted from first breast-related claim from a 
physician to surgery. Treatment initiation more than 84–90 days after diagnosis may be 
associated with reduced survival (Eastman et al., 2013; Jung et al., 2011). Additionally, in a 
study of low-income North Carolina women (44% non-White) McLaughlin et al. (2012) 
found that those with an interval of greater than 60 days between diagnosis and treatment 
initiation had a significantly higher risk of death related to breast cancer (Hazard ratio 
(HR)=1.85, 95% CI, 1.04–3.27, p= .04) and a borderline increased risk of death from all 
causes (HR) = 1.66, 95% CI, 1.00–2.77, p= .05). The interval between abnormal 
mammogram and treatment initiation has been lengthening for all US women over the past 
several decades (Bleicher et al., 2012; Caplan, 2014; Hulvat et al., 2010).
Findings of no significant delay in obtaining diagnostic resolution after an abnormal 
mammogram associated with comorbidities, while ascertaining that the interval between 
diagnostic biopsy and treatment is significantly longer for women with two or more 
comorbidities, parallels others’ observations (Fedewa et al., 2011; Freedman et al., 2013; 
Liederbach et al., 2015. When navigators are available, and when diagnostic centers are 
proactive, women with varying levels of comorbidity may be more likely to move at a fairly 
similar pace (Borugian et al., 2008; Hoffman et al., 2012) in obtaining a diagnosis. 
Qualitative interviews have indicated that facilitators of timely diagnostic procedures also 
include staff and social support (Allen et al., 2008) which may have been distributed 
similarly among women with differing numbers of comorbidities in this study sample. 
However, the interval from diagnostic procedures to treatment involves more complex 
decisions about treatment, and physicians may recommend additional procedures, which 
may contribute to frequent findings of lengthier times for women with more complex 
medical conditions (Ashing-Giwa et al., 2010; Balasubramian et al., 2012; Fedewa et al., 
2011).
Previous research shows strong and consistent associations between number of 
comorbidities and breast cancer survival (Land et al., 2012). Positive associations have also 
been found between comorbidity and treatment delays (Freedman et al., 2013; Liederbach et 
al., 2015). The present results, however, do not show an association between medical care 
delay and comorbidity. In part, this may reflect the study design. Since the primary purpose 
of the investigation was to determine regular mammography use from 2005 to 2008, women 
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who died between 2005 and 2007, and who may have had more severe disease, were not 
included. Conflicting results could also reflect, in part, the wide variety of factors associated 
with timing of resolution and treatment, including patient-level barriers that compromise an 
individual’s ability to access health care services, and system-level factors such as 
communications from providers that are difficult to understand (Katz et al., 2014), presence 
or absence of hospital-academic affiliations (Liederbach et al., 2015), rural location,, or 
lower volume of breast cancer treatment (Freedman et al., 2013). There is evidence that 
older minority women with advanced breast cancer and/or comorbid conditions may have 
pre-treatment impairment in executive functioning (Mandelblattt et al., 2014) that may 
contribute to delays in time from positive biopsy to treatment. Therefore, brief routine 
screening for impaired cognitive functioning (Athilingam et al., 2015), especially among 
women with comorbidities, may be used to alert care providers to needs for additional 
support in order for patients to receive timely care.
Additionally, individualized patient navigation services have been found to reduce the 
number of days from one stage in cancer care to the next (Ferrante et al., 2008; Hoffman et 
al., 2012; Katz et al., 2014; Lee et al., 2013; Markossian et al., 2012). Improved data 
collection in varied clinical settings that includes multiple patient and system-level factors 
could lead to a better understanding of the interplay between these factors (Smedley et al., 
2003).
Limitations of this study include a lack of information about clinical stage at diagnosis as 
well as specific patient- and system-level barriers. Moreover, the data did not include 
information about psychiatric comorbidities such as depression and anxiety (Chang et al., 
2014; Kronman et al. 2012; Goodwin et al., 2004; Morris et al., 2013), which some have 
found to be a mediator of adherence to follow-up of abnormal mammograms and biopsies. 
Future exploration of variations in treatment should examine these kinds of comorbid 
conditions. In addition, while medians were used to compare the results of this study with 
NQMBC benchmarks, the wide ranges in interval duration associated with some variables, 
such as those for women with greater that two comorbid conditions, warrants a closer 
examination in future studies.
Despite these and other limitations, the strengths of the present data, including the 
availability of data from a large national cohort of Medicare beneficiaries, are sufficient to 
provide support for the hypothesis that widening gaps in breast cancer survival between 
Black women and White women may be due, in part, to poorer access to high quality care 
among Black women. While definitive timelines associated with increased harm have yet to 
be established (Kaufman et al., 2010), we agree with Chen et al. (2008) that , “Studies do 
not suggest that there is a threshold below which delay has a lesser impact on the risk of 
local recurrence” (p. 8). Furthermore, the results support the call for continued investigation 
of correlates of treatment delays affecting mammograms, biopsies, and treatments (Tian et 
al., 2012) and suggestions that equalization of timely diagnosis and treatment following 
abnormal screening results is an essential step toward reducing disparities in mortality for all 
women (Bowen et al., 2013; Kiely, 2014). The longer duration of time from diagnosis to 
treatment among Black women in the present data suggests that such equalization may 
remain to be achieved among a significant portion of Medicare beneficiaries.
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Implications for Practice and/or Policy
Improving care for Black women after abnormal mammography outcomes may reduce 
disparities in survival among those diagnosed with breast cancer. Clinical support staff or 
nurse navigators could use electronic flags to draw attention to delays in follow-up, and 
contact women to identify barriers to diagnostic biopsies and treatment following diagnosis. 
Furthermore, at the time a woman is notified of an abnormal mammogram or positive 
biopsy, she could be queried about the potential impact of comorbidities on scheduling and 
following through with biopsies and treatment initiation, which then could be addressed by a 
patient navigator. Documentation of biopsy or treatment delays due to physician-
recommended additional testing, or scheduling difficulties could be used to guide quality 
improvement efforts in clinical settings. In addition, there is evidence that older minority 
women with advanced breast cancer and/or comorbid conditions may have pre-treatment 
impairment in executive functioning (Mandelblatt et al., 2014) that may contribute to delays 
in time from positive biopsy to treatment. Therefore, brief routine screening for impaired 
cognitive functioning, (Athilingam, Visovsky, Elliott, & Rogal, 2015) especially among 
women with comorbidities, may be used to alert care providers to needs for additional 
support in order for patients to receive timely care.
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Table 1
Mean and median number of days between mammogram and biopsy, biopsy to treatment, and mammogram to 




Biopsy to Treatment Mammogram to
Treatment



































































































The 95% confidence interval is in parentheses.
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Table 2
Factors predicting the hazard of a duration longer than NQMBC1 times to biopsy following an abnormal 
mammogram, from biopsy to treatment, and from mammogram to treatment
Mammogram to Biopsy Biopsy to Treatment Mammogram to Treatment











































National Quality Measures for Breast Centers
Ŧ
The 95% confidence interval is in parentheses.
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